Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...

Novo Nordisk’s American depositary receipts tumbled almost 6% Friday after the drugmaker reported mixed results from a study of an experimental weight-loss pill. The pill, monlunabant, helped people ...

Shares were down 4.3% at 1330 GMT, the lowest since August 8, after the company announced headline results from its trial of ...

Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

The Bank of England could cut interest rates to 2.75pc next year, analysts have suggested, amid growing confidence that the ...

The novel drugs work by mimicking the gut hormone GLP-1, which lowers blood sugar and limits the appetite. Treatments such as ...

The bloom may be off the rose for obesity drugs as reports of side effects for high doses of GLP-1 drugs. GLP-1s were ...

Roche's diversified portfolio and ongoing GLP-1 developments offer decent upside with limited downside. Read more about RHHBY ...

Nate Cohn and his colleagues have published the first high-quality survey since KAMALA HARRIS replaced President JOE BIDEN on the ticket that suggests the VP’s hot streak may be coming to an end. The ...

The New York Times: Deep Links Between Alcohol And Cancer Are Described In New Report Adults under age 50 have been developing breast cancer and colorectal cancer at increasingly higher rates ...